Integrating Molecular Sequencing Into the Pathological Diagnosis of Clinically Suspected Non–Small Cell Lung Carcinomas
Modern Pathology · 2023
DOI: 10.1016/j.modpat.2023.100126 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Modern Pathology, 2023. Verfasst von Ying-Chun Lo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Adenocarcinoma, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Cancer panel sequencing has been rapidly adopted into clinical practice for the detection of actionable genetic variants in advanced non-small cell lung carcinomas. Unexpected molecular results may lead to reexamination of the clinical diagnosis; however, this scenario has not been systematically evaluated. We reviewed cancer panel next-generation sequencing results from 1007 consecutive patients performed for the clinical indication of non-small cell lung carcinoma along with the corresponding clinical history and anatomical pathology findings. The final integrative diagnosis was a cancer of extrapulmonary origin in 12 of 1007 patients (1.2%). Molecular evidence supporting the final diagnoses included the detection of an UV radiation-associated mutational signature (n = 6), gene fusions (n = 2), and mutations (n = 4). The integrative diagnoses included undifferentiated melanoma, cutaneous squamous cell, and basal cell carcinomas, thyroid carcinoma, urothelial carcinoma, hepatocellular carcinoma, pancreatic adenocarcinoma, intrahepatic cholangiocarcinoma, and synovial sarcoma. A small but nonnegligible proportion of clinically suspected non-small cell lung carcinomas had a final diagnosis of cancer of extrapulmonary origin after clinical next-generation sequencing. The integration of clinical, microscopic, and molecular evidence can aid diagnosis and guide personalized oncology care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; University of Missouri School of Medicine, Columbia, Missouri.
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: fdong1@bwh.harvard.edu.
Zitieren
APA
Lo, Y. C., Bauer, A. H., Odintsov, I., Siegmund, S. E., Sholl, L. M., & Dong, F. (2023). Integrating Molecular Sequencing Into the Pathological Diagnosis of Clinically Suspected Non–Small Cell Lung Carcinomas. Modern Pathology. https://doi.org/10.1016/j.modpat.2023.100126
Vancouver
Lo YC, Bauer AH, Odintsov I, Siegmund SE, Sholl LM, Dong F. Integrating Molecular Sequencing Into the Pathological Diagnosis of Clinically Suspected Non–Small Cell Lung Carcinomas. Modern Pathology. 2023. doi:10.1016/j.modpat.2023.100126
BibTeX
@article{Lo2023,
author = {Lo, Ying-Chun and Bauer, Anna H and Odintsov, Igor and Siegmund, Stephanie E and Sholl, Lynette M and Dong, Fei},
title = {Integrating Molecular Sequencing Into the Pathological Diagnosis of Clinically Suspected Non–Small Cell Lung Carcinomas},
journal = {Modern Pathology},
year = {2023},
doi = {10.1016/j.modpat.2023.100126}
}
EUVIMED